OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

OSE免疫治疗学和南特大学医院目前正在进行1/2期阳性研究，评估FR104/VEL-101免疫疗法在肾移植中的应用

At the American Transplant Congress 2024 (June 1-5 Philadelphia)

2024年美国移植大会（6月1日至5日，费城）

Nantes, France – June 5, 2024, 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Nantes University Hospital present positive Phase 1/2 analysis from first use of anti-CD28 FR104/VEL-101 in kidney transplantation in oral presentation at the Annual American Transplant Congress (ATC) held in Philadelphia (June 1-5, 2024).

法国南特–2024年6月5日上午7:30 CET–OSE Immunotherapeutics SA（ISIN:FR0012127173；Mnemo:OSE）和南特大学医院在费城举行的年度美国移植大会（ATC）（2024年6月1日至5日）上首次使用抗CD28 FR104/VEL-101进行了肾移植的1/2期阳性分析。

A total of three oral presentations on FR104/VEL-101 were presented at this congress..

在本次大会上，共有三次关于FR104/VEL-101的口头陈述。。

A first oral communication, entitled “First use of FR104, an anti-CD28 molecule in human kidney transplantation”, presented by Pr. Gilles Blancho, Head of the ITUN* at the University Hospital in Nantes / Nantes University and Principal Investigator of the study, reported on the positive data from the completed Phase 1/2 clinical trial FIRsT evaluating FR104/VEL-101 in patients undergoing renal allotransplant.

第一次口头交流题为“FR104（一种抗CD28分子在人肾移植中的首次使用）”，由南特/南特大学大学医院ITUN*负责人兼该研究的首席研究员吉勒斯·布兰乔（Pr.Gilles Blancho）介绍，报告了完成的1/2期临床试验的阳性数据，该试验首先评估了接受同种异体肾移植的患者的FR104/VEL-101。

This study is sponsored and conducted by the University Hospital of Nantes as part of a collaboration agreement with OSE Immunotherapeutics..

这项研究由南特大学医院赞助和进行，作为与OSE免疫治疗公司合作协议的一部分。。

A second oral communication, entitled “Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Fixed-Dose, Subcutaneous (SQ) Administration of VEL-101, an Anti-CD28 Pegylated Monoclonal Antibody Fragment, in Healthy Participants”, presented by OSE Immunotherapeutics partner Veloxis Pharmaceuticals, featured the results from the Company’s Phase 1 dose escalation clinical trial evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending doses of subcutaneous administration of FR104/VEL-101 in healthy participants..

由OSE Immunotherapeutics partner Veloxis Pharmaceuticals提交的第二次口头交流，题为“健康参与者中固定剂量皮下（SQ）施用抗CD28聚乙二醇化单克隆抗体片段VEL-101的安全性，药代动力学（PK）和药效学（PD）”，重点介绍了该公司1期剂量递增临床试验的结果，该试验评估了健康参与者单次递增剂量皮下施用FR104/VEL-101的安全性，耐受性，药效学和药代动力学。。

A third oral communication, entitled “Combined blockade of the CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunity and prolongs survival in cynomolgus cardiac allografts”, presented by the group of Pr. Richard Pierson (Massachusetts General Hospital, Harvard university, Boston, USA), reported on the positive preclinical efficacy data of FR104/VEL-101 injection in monotherapy or in combination with anti-CD40L antibody to protect from acute and chronic heart allograft rejection..

第三次口头交流题为“联合阻断CD154和CD28共刺激途径可减弱致病性同种异体免疫并延长食蟹猴心脏同种异体移植物的存活时间”，由Richard Pierson（美国波士顿哈佛大学马萨诸塞州总医院）报告了FR104/VEL-101注射液在单一疗法或与抗CD40L抗体联合使用以防止急性和慢性心脏同种异体移植物排斥反应中的阳性临床前疗效数据。。

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, said: “We thank the University Hospital of Nantes for this important step with the first clinical study evaluating FR104/VEL-101 in transplanted patients. Our partner Veloxis presented its positive subcutaneous Phase 1 clinical trial results in oral session, which will facilitate dose selection in preparation for a Phase 2 study in kidney transplant recipients.

OSE Immunotherapeutics首席执行官尼古拉斯·波里耶（Nicolas Poirier）表示：“我们感谢南特大学医院（University Hospital of Nantes）迈出了这一重要的一步，首次对移植患者进行了FR104/VEL-101临床研究。我们的合作伙伴Veloxis在口服会议上展示了其阳性皮下1期临床试验结果，这将有助于为肾移植受者的2期研究做准备。

At last, we are excited about the promising preclinical results of our academic collaborator in the field of cardiac transplantation, further enhancing the future market potential.”.

最后，我们对我们的学术合作者在心脏移植领域取得的有希望的临床前结果感到兴奋，这进一步增强了未来的市场潜力。”。

Pr. Gilles Blancho commented: « We are very pleased to share the positive results of the FIRsT study at international congress on post-transplant immune response and one-year safety in patients treated with FR104/VEL-101, developed for years in our own research laboratory, CR2TI**/UMR Inserm 1064. The data presented show the safety of the product used in combination and the first signs of efficacy in kidney transplant recipients with no episodes of acute rejection after one year follow-up in all patients of the study.

吉勒斯·布兰乔（Gilles Blancho）评论道：“我们很高兴分享国际移植后免疫反应和FR104/VEL-101治疗患者一年安全性大会上第一项研究的积极结果，该研究是在我们自己的研究实验室CR2TI**/UMR Inserm 1064中开发的多年。所提供的数据显示了联合使用的产品的安全性，以及该研究所有患者随访一年后无急性排斥反应发生的肾移植受者的首次疗效迹象。

The exploration of FR104/VEL-101’s safety profile seems promising and encourages moving to a Phase 2 trial for patients undergoing renal transplant who require innovative solution.”.

FR104/VEL-101安全性的探索似乎很有希望，并鼓励对需要创新解决方案的肾移植患者进行2期临床试验。”。

The purpose of the FIRsT Phase 1/2 clinical trial is to investigate the safety, tolerability, and pharmacokinetics of FR104/VEL-101, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment, as well as its potential clinical efficacy on acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors (NCT number: NCT04837092).

第一阶段1/2临床试验的目的是研究FR104/VEL-101（一种新型拮抗剂聚乙二醇化抗CD28 Fab'抗体片段）的安全性，耐受性和药代动力学，以及其在接受标准供体同种异体移植的新生肾移植人群中预防急性排斥反应和肾功能的潜在临床疗效（NCT编号：NCT04837092）。

A one-year safety and efficacy of FR-104/VEL-101 treatment assessment was performed after transplantation, including renal function, incidence of rejection and suspected reported adverse events..

移植后进行FR-104/VEL-101治疗评估的一年安全性和有效性，包括肾功能，排斥反应发生率和疑似报告的不良事件。。

Ten patient candidates eligible to a first kidney transplant at low risk of rejection, as planned in the protocol, have been included in the FIRsT study for eight analyzable patients (two patients were screened and enrolled but not transplanted for technical reasons). Tacrolimus (a calcineurin inhibitor) was withdrawn after 6 months post-transplantation.

按照方案的计划，有10名患者候选人有资格以低排斥风险进行首次肾移植，这些患者已被纳入第一项针对8名可分析患者的研究（两名患者因技术原因进行了筛查和登记，但未进行移植）。他克莫司（钙调神经磷酸酶抑制剂）在移植后6个月撤回。

The eight patients completed 1-year treatment with FR104/VEL-101..

这八名患者用FR104/VEL-101完成了1年的治疗。。

No safety alert was detected for FR104/VEL-101. Adverse events were those conventionally observed in kidney transplantation. Pharmacological monitoring made it possible to optimize exposure to FR104/VEL-101 and to maintain high receptor occupancy during the one-year follow-up. With a follow-up of 1 year in all patients, not only no acute rejection under FR104/VEL-101 was observed, and notably no acute rejection episodes occurred after discontinuation of tacrolimus, but also no immunization against the donor occurred.

未检测到FR104/VEL-101的安全警报。不良事件是肾移植中常规观察到的事件。药理学监测可以优化FR104/VEL-101的暴露，并在一年的随访期间保持高受体占有率。所有患者随访1年，不仅没有观察到FR104/VEL-101下的急性排斥反应，而且在停用他克莫司后没有发生急性排斥反应，而且也没有发生针对供体的免疫接种。

One of the key challenges in organ transplantation remains calcineurin inhibitors alternatives with effective immunosuppressive treatments and minimal side effects, particularly on renal function in order to preserve patients’ quality of life, and long-term control of post-transplant immune reaction..

器官移植的关键挑战之一仍然是钙调神经磷酸酶抑制剂替代品，具有有效的免疫抑制治疗和最小的副作用，特别是对肾功能的影响，以保持患者的生活质量，并长期控制移植后的免疫反应。。

* Urology and Nephrology Transplant Institute (ITUN)

*泌尿外科和肾脏移植研究所（ITUN）

** Center for Research in Transplantation and Translational Immunology (CR2TI)

**移植与转化免疫学研究中心（CR2TI）

DETAILS OF THE PRESENTATIONS

演示文稿的详细信息

OSE IMMUNOTHERAPEUTICS

OSE免疫疗法

“First Use of FR104, an Anti-CD28 Molecule in Human Kidney Transplantation, Interim Analysis”

“首次在人肾移植中使用抗CD28分子FR104，中期分析”

Rapid Fire Oral Abstract Session

速射口头摘要会议

Abstract 1050

摘要1050

Tuesday, June 04 - 3:50PM – 4 :00PM

6月4日星期二下午3:50至4:00

G. J. Blancho, Institute of Transplantation - Urologie - Nephrologie (ITUN), Centre Hospitalier Universitaire, Nantes, France

G、 J.Blancho，移植研究所-泌尿科-肾脏科（ITUN），法国南特大学中心医院

VELOXIS PHARMACEUTICALS

VELOXIS制药

“Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Fixed-Dose, Subcutaneous (SQ) Administration of VEL-101, an Anti-CD28 Pegylated Monoclonal Antibody Fragment, in Healthy Participants”

“在健康参与者中，固定剂量皮下（SQ）施用VEL-101（一种抗CD28聚乙二醇化单克隆抗体片段）的安全性，药代动力学（PK）和药效学（PD）”

Rapid Fire Oral Abstract Session

速射口头摘要会议

Abstract 1049

摘要1049

Tuesday, June 04 - 3:40PM 3:50PM

6月4日星期二下午3:40下午3:50

S. Tremblay{1}, A. Abaigar{2}, P. Allton{1}, D. Sardinha{1}, S. Patel{1}, U. Meier-Kriesche{1}, K. Shah{1}, J. Maynard{3}, B. Otulana{1}, {1}Veloxis Pharmaceuticals, Cary, NC, {2}CTI Clinical Trial & Consulting Services, Bilbao, Spain, {3}CTI Clinical Trial & Consulting Services, Cincinnati, OH

S、 Tremblay{1}，A。Abaigar{2}，P。Allton{1}，D。Sardinha{1}，S。Patel{1}，U。Meier Kriesche{1}，K。Shah{1}，J。Maynard{3}，B。Otulana{1}，{1}Veloxis制药，北卡罗来纳州卡里，{2}CTI临床试验与咨询服务，西班牙毕尔巴鄂，{3}CTI临床试验与咨询服务，俄亥俄州辛辛那提

CENTER FOR TRANSPLANTATION SCIENCES, MASSACHUSETTS GENERAL HOSPITAL, HARVARD UNIVERSITY, BOSTON

波士顿哈佛大学麻省总医院移植科学中心

“Combined blockade of the CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunity and prolongs survival in cynomolgus cardiac allografts”

“联合阻断CD154和CD28共刺激途径可减弱食蟹猴心脏同种异体移植物的致病性同种免疫并延长存活时间”

Rapid Fire Oral Abstract Session

速射口头摘要会议

Abstract 860

摘要860

Tuesday, June 04 - 9:45AM 9:55PM

6月4日星期二上午9:45下午9:55

Kohei Kinoshita1, A Maenaka1, Z Habibabady1, I Ileka1, M Ma1, V Diaz1, T Zhang3, N O’Neill3, I Rosales2, S Fogarty4, P Maguire4, B Daugherty4, S Lederman4, U Meier-Kriesche5, N Poirier6, A Azimzadeh1,3, R Pierson III1, 1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, 2 Department of Pathology, Massachusetts General Hospital, Boston, , 3 University of Maryland School of Medicine, Baltimore, 4 Tonix Pharmaceuticals, 5 Veloxis Pharmaceuticals, 6 OSE Immunotherapeutics .

Kohei Kinoshita1，Maenaka1，Z Habibabady1，I Ileka1，M Ma1，V Diaz1，T Zhang3，N O'Neill3，I Rosales2，S Fogarty4，P Maguire4，B Daugherty4，S Lederman4，U Meier-Kriesche5，N Poirier6，A Azimzadeh1,3，R Pierson III1，1波士顿马萨诸塞州总医院移植科学中心，2波士顿马萨诸塞州总医院病理科，3巴尔的摩马里兰大学医学院，4 Tonix Pharmaceuticals，5 Veloxis制药，6 OSE免疫治疗。

ABOUT FR104/VEL-101

关于FR104/VEL-101

FR104/VEL-101 is a pegylated monoclonal antibody fragment that binds to and blocks CD28-mediated effector-T cell co-stimulation, without blocking CTLA-4, an important protein receptor found on T cells that acts as a natural brake on the body’s immune responses. FR104/VEL-101 is, therefore, expected to have a dual-mechanism of action where in a direct manner, it blocks CD28-mediated T cell activation, and in an indirect way, it allows for CTLA-4 mediated immunosuppressive functions..

FR104/VEL-101是一种聚乙二醇化单克隆抗体片段，可结合并阻断CD28介导的效应T细胞共刺激，而不会阻断CTLA-4，CTLA-4是T细胞上发现的一种重要蛋白质受体，可作为人体免疫反应的天然刹车。因此，FR104/VEL-101有望具有双重作用机制，直接阻断CD28介导的T细胞活化，间接阻断CTLA-4介导的免疫抑制功能。。

ABOUT VELOXIS PHARMACEUTICALS

关于VELOXIS PHARMACEUTICALS

Veloxis Pharmaceuticals, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, N.C., USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases.

Veloxis Pharmaceuticals是一家朝日化成公司，是一家全面整合的专业制药公司，致力于改善移植患者的生活。Veloxis总部位于美国北卡罗来纳州卡里，专注于移植患者和严重相关疾病患者使用的药物的全球开发和商业化。

For further information, please visit www.veloxis.com..

欲了解更多信息，请访问www.veloxis.com。。

ABOUT OSE IMMUNOTHERAPEUTICS

关于OSE免疫疗法

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I).

OSE Immunotherapeutics是一家生物技术公司，致力于开发免疫肿瘤学（IO）和免疫炎症（I＆I）领域的一流资产。

The Company’s current well-balanced first-in-class clinical pipeline includes:

该公司目前平衡良好的一流临床渠道包括：

Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company’s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure.

Tedopi®（免疫疗法激活肿瘤特异性T细胞，现成，基于新表位）：这种癌症疫苗是该公司最先进的产品；检查点抑制剂失败后继发耐药的非小细胞肺癌患者的3期临床试验（Atalante 1）的阳性结果。

Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors..

由临床肿瘤学小组赞助的Tedopi®联合其他2期临床试验正在实体瘤中进行。。

OSE-279 (anti-PD1): first positive results in the ongoing Phase 1/2 in solid tumors.

OSE-279（抗PD1）：实体瘤正在进行的1/2期的首次阳性结果。

OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).

OSE-127-lusvertikimab（IL-7受体的人源化单克隆抗体拮抗剂）；正在进行的溃疡性结肠炎第二阶段（赞助商OSE免疫治疗）；正在进行的白血病临床前研究（OSE免疫治疗）。

FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).

FR-104/VEL-101（抗CD28单克隆抗体）：与Veloxis Pharmaceuticals，Inc.在移植中合作开发；正在进行的肾移植1/2期（赞助南特大学医院）；美国成功的第一阶段（赞助商Veloxis Pharmaceuticals，Inc.）。

Anti-SIRPα monoclonal antibody developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.

与勃林格殷格翰合作开发的抗SIRPα单克隆抗体用于晚期实体瘤和心血管肾代谢疾病（CRM）；阳性1期剂量递增导致单药治疗和联合治疗；CRM疾病的第二阶段计划于2024年底启动。

OSE-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.

OSE-230（ChemR23激动剂mAb）与AbbVie合作开发用于慢性炎症。

OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies:

OSE Immunotherapeutics预计将从其三个专有药物发现平台中产生更大的价值，这是其提供下一代一流免疫疗法的宏伟目标的核心：

Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution and optimizing the therapeutic potential of targeting Neutrophils and Macrophages in I&I. OSE-230 (licensed to AbbVie) is the first candidate generated by the platform, additional discovery programs ongoing on new pro-resolutive GPCRs..

ProResolution mAb平台专注于靶向和推进炎症消退，并优化I＆I中靶向中性粒细胞和巨噬细胞的治疗潜力。OSE-230（授权给AbbVie）是该平台产生的第一个候选药物，新的ProResolution GPCR正在进行其他发现程序。。

Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO by targeting immune regulatory receptors expressed by Macrophages and Dendritic cells. BI 765063 and BI 770371 (licensed to Boehringer Ingelheim) are the most advanced candidates generated by the platform.

骨髓检查点平台专注于通过靶向巨噬细胞和树突状细胞表达的免疫调节受体来优化IO中骨髓细胞的治疗潜力。BI 765063和BI 770371（授权给勃林格殷格翰）是该平台产生的最先进的候选者。

Ongoing additional discovery programs, in particular with positive preclinical results obtained in monotherapy with new anti-CLEC-1 mAbs..

正在进行的其他发现计划，特别是在使用新的抗CLEC-1单克隆抗体的单一疗法中获得了积极的临床前结果。。

BiCKI® Platform is a bifunctional fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy.

BiCKI®平台是一种双功能融合蛋白平台，构建在抗PD1的关键骨架成分上，结合新的免疫治疗靶标，以提高抗肿瘤功效。

Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on X and LinkedIn.

有关OSE免疫治疗资产的更多信息，请访问该公司的网站：www.OSE-immuno.com。请在X和LinkedIn上关注我们。

Contacts

联系人

Sylvie Détry

西尔维·德特里

sylvie.detry@ose-immuno.com

sylvie.detry@ose-immuno.com

Nicolas Poirier

尼古拉斯·波里耶

Chief Executive Officer nicolas.poirier@ose-immuno.com

首席执行官nicolas.poirier@ose-immuno.com

French Media: FP2COM

法国媒体：FP2COM

Florence Portejoie

佛罗伦萨Portejoie

fportejoie@fp2com.fr

fportejoie@fp2com.fr

+33 6 07 768 283

+33 6 07 768 283

U.S. Media Contact

U、 美国媒体联系人

RooneyPartners LLC

RooneyPartners有限责任公司

Kate Barrette

凯特·巴雷特

kbarrette@rooneypartners.com

kbarrette@rooneypartners.com

+1 212 223 0561

+1 212 223 0561

Forward-looking statements

前瞻性声明

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate..

本新闻稿包含明确或暗示的信息和声明，这些信息和声明可能被视为OSE免疫治疗方面的前瞻性信息和声明。它们不构成历史事实。这些信息和报表包括财务预测，这些财务预测是基于OSE Immunotherapeutics管理层根据其经验和对历史趋势、当前经济和行业状况、预期未来发展以及他们认为合适的其他因素的看法所做出的某些假设和评估。。

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics.

这些前瞻性陈述包括通常使用条件句的陈述，其中包含动词，如“expect”、“prespect”、“believe”、“target”、“plan”或“estimate”，它们的词尾和词缀以及类似含义的单词。尽管OSE Immunotherapeutics管理层认为前瞻性声明和信息是合理的，但OSE Immunotherapeutics的股东和其他投资者应注意，此类预期的完成本质上受到各种风险的影响，无论是否已知，以及难以预测且通常超出OSE Immunotherapeutics控制的不确定性。

These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

这些风险可能导致实际结果和发展与前瞻性声明中表达、暗示或预测的结果和发展存在重大差异。这些风险包括OSE Immunotherapeutics向AMF提交的公开文件中讨论或确定的风险。这种前瞻性陈述并不能保证未来的表现。

This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements..

本新闻稿仅包含摘要信息，应与2024年4月30日向AMF提交的OSE Immunotherapeutics Universal Registration Document（OSE Immunotherapeutics通用注册文件）一起阅读，包括OSE Immunotherapeutics网站上提供的2023财年年度财务报告。除适用法律要求外，OSE Immunotherapeutics于本新闻稿发布之日发布本新闻稿，不承担更新或修订前瞻性信息或声明的任何义务。。

Attachment

附件

EN_240605_FR104 ATC

EN\U 240605\U FR104 ATC